

UNITED STATES BANKRUPTCY COURT
FOR THE WESTERN DISTRICT OF THE STATE OF OKLAHOMA

IN RE:

Moore Medical Center, LLC

DEBTOR

Case No. 06-12867

Chapter 7

FILED
2013 SEP 27 P 4: 04

CLERK
U.S. BANKRUPTCY COURT
WESTERN DISTRICT OF OK
DEPUTY DD

APPLICATION FOR ORDER DIRECTING PAYMENT
OF FUNDS TO CREDITOR/CLAIMANT PURSUANT TO
11 U.S.C. SECTION 347 AND 28 U.S.C SECTIONS 2041 ET. SEO.

Dilks & Knopik, LLC, Attorney-in-Fact for Baxter International Inc. (the "Claimant") a claimant for the captioned case respectfully requests as follows:


1. Baxter Healthcare was a creditor of the Debtor and was due to receive and the trustee did, in fact, make a distribution from the estate to Baxter Healthcare in the amount of approximately \$4,792.59. Baxter Healthcare was not located and the funds of the creditor were paid into the Court pursuant to 11 U.S.C. Section 347.

2. Pursuant to 11 U.S.C. Section 347 and chapter 129 of title 28, United States Code, the claimant requests that the Court issue an order directing payment to the creditor and the claimant and that payment be made in care of Baxter International Inc. and Dilks & Knopik, LLC, 35308 SE Center St, Snoqualmie, WA 98065.

WHEREFORE, Claimant requests that the Court issue an order directing payment of all funds held by the Court in this case and for such further and other relief as is just and appropriate. The U.S. Attorney for the Western District of Oklahoma has been noticed with a true and correct copy of this application.

Date: July 16, 2013

By:





Brian J. Dilks, Managing Member
Dilks & Knopik, LLC, Attorney in Fact for
Baxter International Inc.

STATE OF WASHINGTON, COUNTY OF KING

On 7/16/2013 before me, personally appeared Brian J. Dilks personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument. WITNESS my hand and official seal.

(SEAL)




Andrew T. Drake, Notary Public
My commission expires on August 9, 2015

**UNITED STATES BANKRUPTCY COURT
FOR THE WESTERN DISTRICT OF THE STATE OF OKLAHOMA**

IN RE:

Moore Medical Center, LLC

DEBTOR

)
)
)
)
)
)

Case No. 06-12867

Chapter 7

CASE HISTORY:

The original dividend check was sent to a Baxter Healthcare. Baxter Healthcare is fully known as Baxter Healthcare Corporation. Baxter Healthcare Corporation is a wholly owned subsidiary of Baxter International, Inc., as evidenced by Exhibit A.

UNITED STATES BANKRUPTCY COURT
WESTERN DISTRICT OF OKLAHOMA

RE: Moore Medical Center, LLC

Case: 06-12867

AUTHORITY TO ACT
Limited Power of Attorney
Limited to one Transaction

Debtor(s)

USED ONLY TO COLLECT FUNDS FROM THE ABOVE REFERENCED CASE

1. Baxter International Inc. with a tax identification number of 36-0781620, ("CLIENT"), appoints Dilks & Knopik, LLC ("D&K"), as its lawful attorney in fact for the limited purpose of recovering, receiving and obtaining information pertaining to the outstanding tender of funds in the amount of \$4,792.59 (the "FUNDS"), including the right to collect on CLIENT's behalf any such funds that are held by a governmental agency or authority.
2. CLIENT grants to D&K the authority to do all things legally permissible and reasonably necessary to recover or obtain the FUNDS held by the governmental agency or authority. This limited authority includes the right to receive all communications from the governmental agency or authority and to deposit checks payable to CLIENT for distribution of the FUNDS to CLIENT, less the fee payable to D&K pursuant to and in accordance with its agreement with CLIENT.
3. D&K may not make any expenditure or incur any costs or fees on behalf of CLIENT without CLIENT's prior written consent.
4. This Authority to Act shall become effective on the below signed date and shall expire upon collection of the aforementioned FUNDS. I authorize the use of a photocopy of this Limited Power of Attorney in lieu of the original.

Shawn M. Ryan
Shawn M. Ryan - Credit Manager

Date

7/8, 2013

Baxter

Shawn Ryan
Manager II, Operations

Baxter Healthcare Corporation
25212 W. IL Route 120
Round Lake, Illinois 60073
T 224.270.1238 F 224.270.3311 F 877.294.7784
shawn_ryan@baxter.com

ACKNOWLEDGMENT

STATE OF ILLINOISCOUNTY OF LAKE


On this 8th day of July, 2013, before me, the undersigned Notary Public in and for the said County and State, personally appeared (name) Shawn M. Ryan known to me to be the person described in and who executed the foregoing instrument, and who acknowledged to me that (circle one) he/she did so freely and voluntarily and for the uses and purposes therein mentioned.

WITNESS my hand and official seal.

NOTARY PUBLIC

Residing at Baxter Healthcare, Round Lake, IL

My Commission expires

3/1/14



Baxter
Northern Illinois



Shawn

Shawn

Ryan

SHAWN DOUGLAS

UNITED STATES BANKRUPTCY COURT
FOR THE WESTERN DISTRICT OF OKLAHOMA

In Re:

Moore Medical Center, LLC

Debtor(s)

Case: 06-12867

Chapter:

AFFIDAVIT OF CREDITOR

State of ILLINOIS

County of LAKE

I, Shawn M. Ryan, Credit Manager of Baxter International Inc., the undersigned creditor in the above referenced case, being first duly sworn upon oath, state as follows:

1. Dilks & Knopik, LLC, 35308 SE Center Street, Snoqualmie, WA 98065 has been granted a power of attorney by me to submit an Application for Payment from Unclaimed Funds seeking payment of claim no. in the amount of \$4,792.59 due and owing to me (or the company I represent) as a creditor in the above referenced bankruptcy case.

2. My name, address and telephone number are as follows:

Baxter International Inc.
Shawn M. Ryan, Credit Manager
25212 W. IL Rte 120 WG1-2S
Round Lake, IL 60073
224.948.2000

3. Substantiate creditor's right to claim, including but not limited to documents relating to sale of company, i.e. purchase agreements and/or stipulation by prior and new owner as to right of ownership of funds. Attach certified copies of all necessary documentation.

4. I (or the entity I represent) have neither previously received remittance for the claim nor have contracted with any other party than the person named in item one above to recover these funds.

I hereby certify that the foregoing statements are true and correct to the best of my knowledge and belief.

Dated: 7/8/2013

Shawn M. Ryan

Shawn M. Ryan

Subscribed and sworn to before me this 8th day of July, 20 13.

Gloria A. Gustafson
Notary Public

(SEAL)

My commission Expires:

3/1/14



Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)

- ☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the fiscal year ended December 31, 2012

OR

- ☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the transition period from _____ **to** _____

Commission file number 1-4448

Baxter
Baxter International Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware

*(State or Other Jurisdiction of
Incorporation or Organization)*

One Baxter Parkway, Deerfield, Illinois
(Address of Principal Executive Offices)

36-0781620

(I.R.S. Employer Identification No.)

60015

(Zip Code)

Registrant's telephone number, including area code 224.948.2000

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class
Common stock, \$1.00 par value

Name of Each Exchange on Which Registered
New York Stock Exchange
Chicago Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files) Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒Non-accelerated filer ☐Accelerated filer ☐Smaller reporting company ☐

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The aggregate market value of the voting common equity held by non-affiliates of the registrant as of June 29, 2012 (the last business day of the registrant's most recently completed second fiscal quarter), based on the per share closing sale price of \$53.15 on that date and the assumption for the purpose of this computation only that all of the registrant's directors and executive officers are affiliates, was approximately \$29 billion. There is no non-voting common equity held by non-affiliates of the registrant.

The number of shares of the registrant's common stock, \$1.00 par value, outstanding as of January 31, 2013 was 545,928,648.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant's definitive 2013 proxy statement for use in connection with its Annual Meeting of Shareholders to be held on May 7, 2013 are incorporated by reference into Part III of this report.

Exhibit A

EXHIBIT 21

Subsidiaries of Baxter International Inc.

Subsidiary	Organized under laws of	% owned by immediate parent(1)
Baxter International Inc.	Delaware	
Baxter Colorado Holding Inc.	Colorado	100
Baxa Corporation	Colorado	100
Baxter Healthcare Corporation	Delaware	100
Baxter Pharmaceutical Solutions LLC	Delaware	100
BioLife Plasma Services L.P.	Pennsylvania	99(2)
Baxter Holding Services Company	Delaware	100
Synovis Life Technologies, Inc.	Minnesota	100
Baxter World Trade Corporation	Delaware	100
Baxter Corporation	Canada	100
Baxter de Venezuela, C.A.	Venezuela	100
Baxter Export Corporation	Nevada	100
Baxter Global Holdings Inc.	Delaware	100
Baxter Healthcare Pty Ltd	Australia	99.999(2)
Baxter Healthcare Limited	Taiwan	100
Baxter Holding Mexico, S. de R.L. de C.V.	Mexico	99.999(2)
Baxter S.A. de C.V.	Mexico	99.99(2)
Baxter Holdings Limited	Japan	100
Baxter Limited	Japan	100
Baxter Sales and Distribution Corp.	Delaware	100(3)
Baxter Healthcare Corporation of Puerto Rico	Alaska	100
Baxter Global Holdings II Inc.	Delaware	100
Baxter Holding B.V.	The Netherlands	100
ApaTech Limited	United Kingdom	100
Baxter AG	Switzerland	100
Baxter Argentina S.A.	Argentina	93.08(2)
Baxter Healthcare (Holdings) Limited	United Kingdom	100
Baxter Healthcare Limited	United Kingdom	100
Baxter (Hellas) EPE	Greece	99.8(2)
Baxter Healthcare Holding GmbH	Switzerland	100
Baxter Healthcare SA	Switzerland	100
Baxter Healthcare Pharmaceutical Limited	United Kingdom	100
Baxter Pacific Investments Pte Ltd	Singapore	100
Baxter (China) Investment Co., Ltd.	China	100
Baxter Healthcare (Guangzhou) Company Ltd	China	87.5
Baxter Healthcare (Suzhou) Company Ltd.	China	100
Baxter Healthcare (Shanghai) Company Ltd	China	100
Baxter (India) Private Limited	India	99.99(2)
Baxter Healthcare Trading (Shanghai) Company Ltd.	China	100
Baxter Productos Medicos LTDA	Costa Rica	100
Baxter Trading GmbH	Switzerland	100
Baxter BioScience Manufacturing Sarl	Switzerland	100
Baxter Innovations GmbH	Austria	100
Baxter AG	Austria	100
Baxter Hospitalar Ltda.	Brazil	99.999(2)
Baxter Incorporated	Republic of Korea	100
Baxter Netherlands Holding B.V.	The Netherlands	100
Baxter S.A.	Belgium	99.97(2)
Eczacıbaşı-Baxter Hastane Ürünleri Sanayi ve Ticaret A.Ş.	Turkey	49.999(4)
Baxter Deutschland Holding GmbH	Germany	94(2)
Baxter Deutschland GmbH	Germany	100
Baxter Oncology GmbH	Germany	100
Baxter World Trade SPRL	Belgium	99.999(2)
Baxter World Trade Italy S.R.L.	Italy	100
Baxter S.p.A.	Italy	98.98(2)
Baxter Manufacturing S.p.A.	Italy	98.98(2)
Bieffe Medical S.p.A.	Italy	99.46
Bieffe Medical Nederland NV	The Netherlands	100
Sapa Prodotti Plastici Sagl	Switzerland	100
Laboratorios Baxter S.A.	Delaware	100
RTS Worldwide Holdings Inc.	Delaware	100
RTS Americas Inc.	Delaware	100
RTS Colombia Ltda.	Colombia	99.51(2)
RTS S A S	Colombia	100

Subsidiaries omitted from this list, considered in aggregate as a single subsidiary, would not constitute a significant subsidiary. All subsidiaries set forth herein are reported in the Company's financial statements through consolidation or under the equity method of accounting.

- (1) Including nominee shares.
- (2) Remaining shares owned by the Company, or other subsidiaries of the Company.
- (3) Of common stock, with preferred stock held by Baxter Healthcare Corporation.
- (4) Baxter's total ownership in this joint venture is 50%. The remaining .001% is owned by other Baxter entities.

Exhibit A